WO2024209270 - METHODS AND COMPOSITIONS FOR CANCER TREATMENT USING RECOMBINANT POLYPEPTIDES
National phase entry is expected:
Publication Number
WO/2024/209270
Publication Date
10.10.2024
International Application No.
PCT/IB2024/000183
International Filing Date
05.04.2024
Title **
[English]
METHODS AND COMPOSITIONS FOR CANCER TREATMENT USING RECOMBINANT POLYPEPTIDES
[French]
MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DU CANCER À L'AIDE DE POLYPEPTIDES RECOMBINANTS
Applicants **
INFINITOPES LIMITED
BioEscalator Innovation Building
Oxford University
696 Roosevelt Drive
Oxford
Oxfordshire OX3 7FZ, GB
Inventors
LEE, Lian, Ni
20.06 Bioescalator Innovation Building
Oxford University
696 Roosevelt Drive
Oxford
Oxfordshire OX3 7FZ, GB
KWOK, Jonathan
20.06 Bioescalator Innovation Building
Oxford University
696 Roosevelt Drive
Oxford
Oxfordshire OX3 7FZ, GB
TONG, Orion
20.06 Bioescalator Innovation Building
Oxford University
696 Roosevelt Drive
Oxford
Oxfordshire OX3 7FZ, GB
CHINNAKANNAN, Senthil
20.06 Bioescalator Innovation Building
Oxford University
696 Roosevelt Drive
Oxford
Oxfordshire OX3 7FZ, GB
Priority Data
63/457,918
07.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5789 | |
| EPO | Filing, Examination | 79396 | |
| Japan | Filing | 538 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 31835 |
Total: 118133 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed hereopin are methods for the treatment of cancer in a human subject comprising administration of a recombinant polypeptide comprising a cancer-specific CD8+ T cell epitope. Peptides recognized by major histocompatibility complex (MHC) molecules can activate a T cell immune response to target cancer cells in a subject. The present disclosure furthermore provides cancer-specific CD8+ T cell epitopes restricted to MHC molecules expressed by specific HLA-Alleles in a subject. The present disclosure furthermore provides a composition encoding the recombinant polypeptide which is capable of eliciting an inflating memory CD8+ T cell response.[French]
La divulgation concerne des méthodes de traitement du cancer chez un sujet humain comprenant l'administration d'un polypeptide recombinant contenant un épitope de lymphocyte T CD8+ spécifique du cancer. Les peptides reconnus par des molécules du complexe majeur d'histocompatibilité (CMH) peuvent activer une réponse immunitaire des lymphocytes T pour cibler des cellules cancéreuses chez un sujet. La présente divulgation concerne également des épitopes de lymphocytes T CD8+ spécifiques du cancer restreints à des molécules du CMH exprimées par des allèles HLA spécifiques chez un sujet. La présente divulgation concerne en outre une composition codant pour le polypeptide recombinant qui peut de déclencher une réponse d'inflation des lymphocytes T CD8+ à mémoire.